Ticker

Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) Director Bruce Booth sold 4,159 shares of the stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $89.97, for a total transaction of $374,185.23. Following the sale, the director owned 4,159 shares of the company's stock, valued at $374,185.23.

Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) COO Jeremy Chadwick sold 5,251 shares of the business's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total transaction of $472,590.00. Following the transaction, the chief operating officer owned 61,202 shares of the

Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.

Kymera Therapeutics remains a "Strong Buy", driven by positive phase 1b data for KT-621 in atopic dermatitis and pipeline expansion. KT-621 achieved a mean 63% EASI reduction and 40% pruritus NRS reduction, supporting advancement into phase 2b BROADEN2 [AD] and BREADTH [asthma] trials. Both AD and asthma programs received FDA Fast Track Designation, with mid-2027 [BROADEN2] and late-2027 [BREADTH] data readouts as…

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track designation previously granted for KT-621 for moderate to severe AD WATERTOWN, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…